Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity

Hakomori, 1996, Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism, Can Res, 56, 5309 Lloyd, 1987, Blood group antigens as markers for normal differentiation and malignant changes in human tissues, Am J Clin Pathol, 87, 129, 10.1093/ajcp/87.1.129 Zhang, 1998, Selection of tumor antigens as targets for immune attack using immunohistochemistry: III protein antigens, Clin Cancer Res, 4, 2669 Zotter, 1988, Tissue and tumor distribution of human polymorphic epithelial mucin, Cancer Rev, 11, 55 Gendler, 1990, Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin, J Biol Chem, 265, 15286, 10.1016/S0021-9258(18)77254-2 Gendler, 1988, A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats, J Biol Chem, 263, 12820, 10.1016/S0021-9258(18)37632-4 Lloyd, 1996, Comparison of O-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines, J Biol Chem, 271, 33325, 10.1074/jbc.271.52.33325 Burchell, 1989, A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes, Int J Cancer, 44, 691, 10.1002/ijc.2910440423 Livingston, 1993, GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3, Vaccine, 11, 1199, 10.1016/0264-410X(93)90043-W Livingston, 1987, Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients, Proc Natl. Acad Sci USA, 84, 2911, 10.1073/pnas.84.9.2911 Helling, 1994, Increased immunogenicity of GD3 conjugate vaccines: comparison of various carrier proteins and selection of GD3-KLH for further testing, Cancer Res, 54, 197 Kim, 1999, Comparison of the effect of different immunological adjuvants on the antibody and T cell response to immunization with MUC1-KLH and GD3-KLH conjugate vaccines, Vaccine, 18, 597, 10.1016/S0264-410X(99)00316-3 Kim, 2000, Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates, Vaccine, 19, 530, 10.1016/S0264-410X(00)00195-X Zhang, 1996, Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice, Cancer Res, 55, 3364 Gilewski, 2000, Vaccination of high risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21, Clin Cancer Res, 6, 1693 Gilewski, 2001, Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial, Proc Natl Acad Sci USA, 98, 3270, 10.1073/pnas.051626298 Chapman, 2000, Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: A trial comparing doses of GD2-KLH, Clin Cancer Res, 6, 4658 Schodel, 1994, Hepatitis B virus core particles as a vaccine carrier moiety, Int Rev Immunol, II, 153, 10.3109/08830189409061723 Schodel, 1992, The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity, J Virol, 66, 106, 10.1128/JVI.66.1.106-114.1992 Schodel, 1993, Avirulent salmonella expressing hybrid hepatitis B virus core/preS genes for oral vaccine, Vaccine, 11, 143, 10.1016/0264-410X(93)90010-U Schodel, 1993, Structure of hepatitis B virus core and E antigens: a single precore amino acid prevents nucleocapsid assembly, J Biol Chem, 268, 1332, 10.1016/S0021-9258(18)54079-5 Milich, 1995, The hepatitis nucleocapsid as a vaccine carrier moiety, Ann NY Acad Sci, 754, 187, 10.1111/j.1749-6632.1995.tb44451.x Schodel, 1996, Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes, J. Biotechnol, 44, 91, 10.1016/0168-1656(95)00118-2 Paoletti, 2001, Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen, Vaccine, 20, 370, 10.1016/S0264-410X(01)00364-4 Zheng, 1992, The structure of hepadnaviral core antigens. Identification of free thiols and determination of the disulfide bonding pattern., J Biol Chem, 267, 9422, 10.1016/S0021-9258(19)50440-9 Ragupathi, 2002, Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines, Vaccine, 20, 1030, 10.1016/S0264-410X(01)00451-0 Helling, 1995, GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21, Cancer, 2783 Wynne, 1999, The crystal structure of the human hepatitis B virus capsid, Mol Cell, 3, 771, 10.1016/S1097-2765(01)80009-5 Bringas, 1997, Folding and assembly of hepatitis B virus core protein: a new model proposal, J Struct Biol, 118, 189, 10.1006/jsbi.1997.3846 Crowther, 1994, Three-dimensional structure of hepatitis B virus core particles determined by cryomicroscopy, Cell, 77, 943, 10.1016/0092-8674(94)90142-2 Kenney, 1995, Evolutionary conservation in the hepatitis B core structure: comparison of human and duck cores, Structure, 3, 1009, 10.1016/S0969-2126(01)00237-4 Lobaina, 2002, Mucosal immunogenicity of the hepatitis B core antigen, Biochem Biophys Res Commun, 300, 745, 10.1016/S0006-291X(02)02897-8 Lazdina, 2001, Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptors on naïve B cells, J Virol, 75, 6367, 10.1128/JVI.75.14.6367-6374.2001 Milich, 1986, The nucleocapsid of hepatitis B virus is both a T-cell-independent and T-cell-dependent antigen, Science, 234, 1398, 10.1126/science.3491425